Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Clinical trial NCT06169215 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06169215
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-23
- Primary completion
- 2026-09-30
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.